Imuldosa

Ustekinumab, the active ingredient in Imuldosa, is a monoclonal antibody (IL‑12/23 antagonist) presented as a sterile solution for subcutaneous use. It is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease in adult patients.

GNH USA supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable cold‑chain logistics and regulatory compliance for biologic medicines. The company maintains stringent quality controls and provides comprehensive documentation to meet regional health authority requirements.

Imuldosa (ustekinumab) targets the interleukin‑12/23 pathway and is used in several immune‑mediated inflammatory diseases.

- Plaque psoriasis: reduces skin lesions and improves quality of life in patients with moderate to severe disease. - Psoriatic arthritis: alleviates joint inflammation and slows disease progression. - Crohn's disease: induces and maintains remission of intestinal inflammation in adults.

Adverse reactions may occur with any biologic therapy and should be monitored.

Common Side Effects: - Injection site pain or erythema. - Upper respiratory tract infection. - Headache. - Fatigue. - Nausea. - Diarrhea.

Serious or Rare Side Effects: - Severe infections, including tuberculosis. - Malignancies such as lymphoma. - Anaphylaxis or severe hypersensitivity reactions. - Worsening of inflammatory bowel disease. - Demyelinating disorders. - Cardiovascular events.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential complications.

- Screen for active infections: assess patient history before starting treatment. - Monitor for signs of infection: advise patients to report fever, cough, or chills promptly. - Assess vaccination status: avoid live vaccines during therapy. - Conduct tuberculosis testing prior to use. - Discuss pregnancy and lactation risks with the healthcare provider. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab may interact with other agents that affect immune function or vaccine efficacy.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause infection. - Other immunosuppressants (e.g., azathioprine, methotrexate): increased risk of serious infection. - Combined cytokine inhibitors (e.g., anti‑TNF agents): potential additive immunosuppression.

Moderate Interactions (Monitor Closely): - Non‑live vaccines: may have reduced efficacy, monitor immune response. - Cytochrome P450 substrates: minimal effect but monitor therapeutic levels if clinically indicated.